Potential utility of myocardial blood flow quantification with SPECT in a patient undergoing treatment for breast cancer
Résumé
Cardio-oncology is rapidly developing and aims to optimize diagnosis and management of cardiac complications of cancer treatment. PET can detect the presence of microvascular disease (MVD). Yet, limited clinical studies have applied cardiac PET to monitor for cancer therapy–related cardiotoxicity, with small number of patients, suggesting inverse correlations between Myocardial Flow Reserve (MFR) reduction after parietal radiotherapy (RT) (1, 2), mainly in the anterior territory, and after anthracyclines and RT (3). An animal longitudinal study recently reported MVD due to anthracyclines without contractile abnormality (4). MFR was also suggested as a risk stratification biomarker among breast cancer patients (5).